1 domain / 2 areas / 1 specialization
Otsuka
Data updated
Otsuka Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company within the Otsuka group, focused on creating and commercializing medicines and nutraceutical products. Its corporate profile lists its head office in Chiyoda-ku, Tokyo, Japan. The company describes itself as a total healthcare company with global operations and collaboration across academia and venture partners.
In the psychedelic ecosystem, Otsuka is relevant because it has moved into adjacent neuropsychiatric and rapid-acting treatment areas through acquisitions and research collaborations. In 2025 it announced a joint research agreement with Keio University on infrastructure development for the social implementation of psychedelics in Japan, and in 2026 it announced and then completed its acquisition of Transcend Therapeutics, whose lead program TSND-201 is described as a rapid-acting neuroplastogen for PTSD.
Investor Context
Institutional InvestorsInvestment Context
This stakeholder is listed as an Institutional Investor within Institutional Investors. Its public geography context is global. Public stage signals include Growth / Late Stage, Public Markets, and Multi-Stage. Public focus areas include Drug Development.
Public Portfolio Examples
- Mindset Pharmastrategic acquisition - undisclosed - Sep 1, 2023
- Transcend Therapeuticsstrategic acquisition - $1.225 billion potential consideration - Mar 27, 2026
Otsuka is best understood as a large pharmaceutical strategic investor rather than a traditional venture fund. Its public activity points to a portfolio orientation in psychiatric, neurological, and CNS-adjacent assets, combining internal drug development, acquisitions, and collaborations with academic and venture partners. Its psychedelic relevance is indirect but meaningful: the company has publicly backed research infrastructure for psychedelic use in Japan and acquired Transcend Therapeutics, which develops a rapid-acting neuroplastogen for PTSD. That positioning suggests an interest in next-generation mental health therapeutics and related scientific platforms.
Investor Type
Institutional Investor
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Recorded Investments
Sep 1, 2023
strategic acquisition - undisclosed
A strategic move into next-generation psychiatric and neurological drug development, with explicit relevance to psychedelic-adjacent chemistry and CNS R&D.
Otsuka Pharmaceutical to Acquire Mindset PharmaMar 27, 2026
strategic acquisition - $1.225 billion potential consideration
Transcend's lead asset TSND-201 is described by Otsuka as a rapid-acting neuroplastogen for PTSD, making this directly relevant to psychedelic-adjacent therapeutics.
Otsuka Pharmaceutical to Acquire Transcend TherapeuticsQuick Facts
- Founded
- 1921
- HQ
- Head office: 2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-8535, Japan
- Website
- Visit